RE:RE:RE:Meeting!!!
Kalytera AGM adjourned to Aug. 3
2018-07-27 17:17 ET - News Release
Mr. Robert Farrell reports
KALYTERA THERAPEUTICS ANNOUNCES ADJOURNMENT OF 2018 ANNUAL AND SPECIAL MEETING
Kalytera Therapeutics Inc.'s annual and special meeting of Kalytera shareholders, scheduled for, and convened on, July 27, 2018, has been adjourned due to the lack of a requisite quorum.
In accordance with the articles of the company, the annual and special meeting has been adjourned to Aug. 3, 2018, at 10 a.m. at Torys LLP, 79 Wellington St. West, 33rd floor, TD South Tower, Toronto, Ont.
The company's articles provide that the quorum for the transaction of business at a meeting of shareholders is two shareholders represented in person or by proxy holding in aggregate at least 10 per cent of the issued shares.
At the adjourned meeting to be held on Aug. 3, 2018, the company's articles provide that if the 10-per-cent quorum is not present, then the shareholders represented in person or by proxy at the meeting shall nonetheless constitute a quorum.
The company's notice of meeting, information circular and form of proxy in respect of the annual meeting, available on SEDAR and mailed to the Kalytera shareholders, remain unchanged.
Forms of proxy which have been duly submitted and were valid for the meeting will still be valid at the adjourned meeting unless properly revoked.
The forms of proxy that accompanied the notice of meeting and information circular, which were sent to the shareholders, can still be used for the adjourned meeting. Any registered shareholder who wishes to appoint a proxy to attend and vote at the adjourned meeting and has not yet done so should note that a valid form of proxy may now be received by TSX Trust Company, 200 University Ave., Suite 300, Toronto, Ont., M5H 4H1, up to 10 a.m. Toronto time on Aug. 1, 2018. Proxies received after this time may not be accepted; however, the chair of the adjourned meeting may determine, in his sole discretion, to waive this deadline or to accept a proxy that is delivered in person to the chair at the adjourned meeting as to any matter in respect of which a vote has not already been cast.
About Kalytera Therapeutics Inc.
Kalytera Therapeutics is pioneering the development of cannabidiol (CBD) therapeutics. Through its proven leadership, drug development expertise and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of CBD medicines for a range of important unmet medical needs, with an initial focus on graft versus host disease and treatment of acute and chronic pain.